Human immunodeficiency virus immunotherapy using a retroviral vector

Current Topics in Microbiology and Immunology

Volumn 226, Issue , 1997, Pages 145-160

  Warner, J F ^a,b   Jolly, D J ^a   Merritt, J ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Inex Pharmaceuticals   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; EXPRESSION VECTOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOTHERAPY; MOLONEY LEUKEMIA ONCOVIRUS; MOUSE; NONHUMAN; PRIMATE; PRIORITY JOURNAL; RETROVIRUS; REVIEW;

ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; GENETIC VECTORS; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; RETROVIRIDAE;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLONEY MURINE LEUKEMIA VIRUS; ONCOVIRINAE; PRIMATES; UNIDENTIFIED RETROVIRUS;

EID: 0031458296     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Review

References (11)

1. Boshart M, Weber F, Jahn G, Dorsch-Hasler K, Fleckenstein B, Schaffner W (1985) A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 41:521-530
2. Braciale TJ, Morrison LA, Sweetser MT, Sambrook J, Gething M-J, Braciale VL (1987) Antigen presentation pathways of class I and class II MHC-restricted T lymphocytes. Immunol Rev 98:95-114
3. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK (1993) Vesicular stomatitis virus G glyco-protein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 90:8033-8037
4. Carmichael A, Jin X, Sissons P, Borysiewicz L ( 1993) Quantitative analysis of the human immunodeficiency virus type I (HIV-I)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV- I .infection: differential CTL responses to HIV- I and Epstein Barr virus in late disease. J Exp Med 177:249-256
5. Chada S, Dejesus CE, Townsend K, Lee WTL, Laube L, Jolly DJ, Chang SMW, Warner JF (1993) Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type I (HIV- 1) strains my murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes. J Virol 67:3409-3417
6. Connor RI, Mohri H, Cao Y, Ho DD (1993) Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol 67:1772-1778
7. Germain RN, Margulies DH (1993) The biochemistry and cell biology of antigen processing and presentation. Annual Rev Immunol 11:403-450
8. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M (1995) Rapid turnover of plasma virions and CD4 lymphocytes in HIV- I infection. Nature 373:123-126
9. Hoffenbach A, Langlade-Demoyen P, Dadaglio G, Vilmer E, Michel F, Mayaud C, Autran B, Plata F (1989) Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans. J Immunol 142:452-460
10. Irwin MJ, Laube LS, Lee V, Austin M, Chada S, Anderson C-G, Townsend K, Jolly DJ, Warner JF (1994) Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates. J Virol 68:5036-5044
11. Kast WM, Bronkhorst AM, De waal LP, Melief CJM (1986) Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection. J Exp Med 164:723-738